NBIX News and Press, Neurocrine Biosciences Inc. From 03/29/23

2023-03-29 06:54:35 ET Neurocrine Biosciences ( NASDAQ: NBIX ) announced late Tuesday that Teva Pharmaceutical  ( NYSE: TEVA ) has agreed to delay the launch of generic versions of its tardive dyskinesia therapy Ingrezza, resolving a patent dispute between the two. ...

Neurocrine Biosciences to Present at the Stifel 2023 CNS Days PR Newswire SAN DIEGO , March 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday , March 28, 2023. E...

2023-03-13 12:59:09 ET Teva Pharmaceutical Industries ( NYSE: TEVA ) has ended recruitment for a phase 3 trial of Austedo (deutetrabenazine) to treat abnormal involuntary movements with cerebral palsy ("CP"). Recruitment stopped because the parent study , which was loo...

Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning PR Newswire SAN DIEGO , M...

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference PR Newswire SAN DIEGO , March 9, 2023 /PRNewswire/ -- Neurocrine Bios...

Neurocrine Biosciences to Participate at Investor Conferences in March PR Newswire Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN DIEGO , March 8, 2023 ...

2023-03-08 08:46:08 ET Cantor Fitzgerald launched its coverage on Karuna Therapeutics ( NASDAQ: KRTX ) with a Neutral rating and a $214 price target, citing its lead product candidate KarXT, an oral therapy which modulates muscarinic receptors in the central nervous system and o...

2023-03-04 13:45:00 ET A record $138B was invested by the 15 largest pharmaceutical companies in 2022, a staggering 43% increase since 2017, according to an IQVIA report. That $138B accounted for ~19% of these companies' overall sales. IQVIA also found that although biopharma in...

New data from Neurocrine Biosciences ( NASDAQ: NBIX ) found that improvements were seen over 48 weeks with the use of Ingrezza (valbenazine) for tardive dyskinesia. Results from the KINECT 3-extension and KINECT 4 studies indicated that at 48 weeks, more than 80% of par...

Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting PR Newswire SAN DIEGO , March 3, 2023 ...